Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Exclusion Criteria

• •1. Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy.
• •2. Presence of locally advanced, unresectable disease, regardless of disease stage or presence of metastases.
• •3. Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose.
• •4. Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.
• •5. Received live or attenuated live vaccines within 4 weeks prior to enrollment or expected to require live or attenuated live vaccines during the study or within 5 months after the last dose of tislelizumab.
• •6. Any condition requiring systemic corticosteroid therapy (prednisone or equivalent \>10 mg/day) or other immunosuppressive therapy within 14 days prior to the first dose of the study drug, which the investigator believes may affect the study treatment.
• •7. Active autoimmune disease requiring systemic treatment, which the investigator believes may affect the study treatment.
• •8. Interstitial lung disease, non-infectious pneumonitis, or uncontrolled other diseases, including diabetes, pulmonary fibrosis, acute lung disease, etc., which the investigator believes may affect the study treatment.
• •9. History of major diseases or clinical manifestations that may affect organ system function, which the investigator believes may affect the study treatment.
• •10. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment within 14 days prior to the first dose of the study drug (including tuberculosis infection, etc.).
• •11. Known history of human immunodeficiency virus (HIV) infection.
• •12. Previously undergone allogeneic stem cell transplantation or organ transplantation.